Evaluation of breast cancer screening programmes: candidate performance indicators and their association with breast cancer mortality

dc.contributor.author
Canelo Aybar, Carlos
dc.contributor.author
Castells, Xavier
dc.contributor.author
ECIBC Contributor Group
dc.date.accessioned
2026-03-07T08:42:19Z
dc.date.available
2026-03-07T08:42:19Z
dc.date.issued
2026-03-06T15:46:00Z
dc.date.issued
2026-03-06T15:46:00Z
dc.date.issued
2025
dc.date.issued
2026-03-06T15:46:00Z
dc.identifier
Canelo-Aybar C, Alonso-Coello P, Muratov S, Tarride JE, Dimitrova N, Giusti F, Borisch B, Castells X, Duffy SW, Fitzpatrick P, Follmann M, Giordano L, Hofvind S, Lebeau A, Quinn C, Torresin A, Giorgi Rossi P, Schunemann H, Nystrom L, Broeders M; ECIBC contributor group. Evaluation of breast cancer screening programmes: candidate performance indicators and their association with breast cancer mortality. Breast. 2025;84:104621. DOI: 10.1016/j.breast.2025.104621
dc.identifier
0960-9776
dc.identifier
https://hdl.handle.net/10230/72721
dc.identifier
http://dx.doi.org/10.1016/j.breast.2025.104621
dc.identifier.uri
https://hdl.handle.net/10230/72721
dc.description.abstract
Aim: Evaluation of a breast cancer (BC) screening programme is necessary to ensure its quality. Performance measurements might be prioritized considering the association with outcomes related to BC mortality. We piloted an approach to explore the association of selected performance measurements with incidence-based BC mortality (IBM). Methods: We performed an ecological analysis of aggregated data from regional or national population-based cancer registries and BC screening programmes in Europe, using 13 performance indicators. We built a panel data (longitudinal cross-sectional) regression model to estimate the association between screening performance measurements and IBM rates. Results: We included data of 9 programmes and registries from Italy, Spain, Norway, Ireland and the Czech Republic. The number of screening years included in the dataset ranged from 5 to 20 years. In adjusted panel analyses, higher screening coverage, breast cancer detection rates (BCDR prevalent and subsequent rounds), node-negative proportion, and episode sensitivity were associated with lower incidence-based mortality (IBM), whereas a higher interval cancer rate was associated with higher IBM. The association for recall rate in subsequent examinations was small and imprecise. Conclusion: Our pilot approach suggests association of several performance indicators with IBM. These indicators were related to the implementation of the screening programme (screening coverage), sensitivity (BC detection rate), and efficiency (recall rate). Further studies with larger datasets and individual data may confirm these findings.
dc.format
application/pdf
dc.format
application/pdf
dc.language
eng
dc.publisher
Elsevier
dc.relation
Breast. 2025;84:104621
dc.rights
© 2025 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Breast Neoplasms/diagnostic imaging
dc.subject
Early detection of Cancer/methods
dc.subject
Female
dc.subject
Mass screening/methods
dc.subject
Program evaluation
dc.subject
Quality indicators, health care/standards
dc.title
Evaluation of breast cancer screening programmes: candidate performance indicators and their association with breast cancer mortality
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)